-+ 0.00%
-+ 0.00%
-+ 0.00%

ALNYLAM TO SHARE PROGRESS ACROSS ITS TRANSTHYRETIN AMYLOIDOSIS FRANCHISE INCLUDING ADDITIONAL ANALYSES OF THE HELIOS-B PHASE 3 STUDY RESULTS AT HEART FAILURE 2025 CONGRESS

Reuters·05/12/2025 11:00:01

Please log in to view news